Serotonin Syndrome
Serotonin Syndrome is a topic covered in the Washington Manual of Medical Therapeutics.
To view the entire topic, please log in or purchase a subscription.
The Washington Manual is an award-winning, complete mobile solution for nurses and students. Look up information on diseases, tests, and procedures; then consult the database with 5,000+ drugs or refer to 65,000+ dictionary terms. Explore these free sample topics:
-- The first section of this topic is shown below --
General Principles
- Serotonin syndrome is a clinical condition of neuromuscular abnormalities, mental status changes, and hyperthermia in patients exposed to serotonergic xenobiotics.
- Serotonin syndrome is a spectrum of disease that ranges from mild to life-threatening.1
- Some authors prefer the term “serotonin toxicity” or “serotonin excess” for all but the sickest patients.
- Mild serotonin excess may not require any treatment or medical evaluation.
- Serotonin syndrome classically develops when two or more serotonergic xenobiotics are coadministered, but it may also occur following an acute overdose of one or more serotonergic xenobiotics, dose titration of serotonergic xenobiotics, and initiation of therapy with a single serotonergic xenobiotic.
Pathophysiology
- Serotonin syndrome is thought to occur due to excessive stimulation of 5HT1 and 5HT2 receptors.
- Many classes of xenobiotics have been implicated in the development of the serotonin syndrome.
- Psychotropics: SSRIs, TCAs, serotonin–norepinephrine reuptake inhibitors (SNRIs), MAO inhibitors, other atypical serotonergic antidepressants, bupropion, lithium, amphetamines, certain atypical antipsychotics
- Opioids: meperidine, tramadol, dextromethorphan, and possibly fentanyl
- Other pharmaceuticals: linezolid, triptans, valproate, lamotrigine, bromocriptine, methylene blue
- Recreational drugs: methamphetamine and other amphetamines, cocaine, serotonergic hallucinogens (MDMA, psilocybin, tryptamine derivatives)
-- To view the remaining sections of this topic, please log in or purchase a subscription --
General Principles
- Serotonin syndrome is a clinical condition of neuromuscular abnormalities, mental status changes, and hyperthermia in patients exposed to serotonergic xenobiotics.
- Serotonin syndrome is a spectrum of disease that ranges from mild to life-threatening.1
- Some authors prefer the term “serotonin toxicity” or “serotonin excess” for all but the sickest patients.
- Mild serotonin excess may not require any treatment or medical evaluation.
- Serotonin syndrome classically develops when two or more serotonergic xenobiotics are coadministered, but it may also occur following an acute overdose of one or more serotonergic xenobiotics, dose titration of serotonergic xenobiotics, and initiation of therapy with a single serotonergic xenobiotic.
Pathophysiology
- Serotonin syndrome is thought to occur due to excessive stimulation of 5HT1 and 5HT2 receptors.
- Many classes of xenobiotics have been implicated in the development of the serotonin syndrome.
- Psychotropics: SSRIs, TCAs, serotonin–norepinephrine reuptake inhibitors (SNRIs), MAO inhibitors, other atypical serotonergic antidepressants, bupropion, lithium, amphetamines, certain atypical antipsychotics
- Opioids: meperidine, tramadol, dextromethorphan, and possibly fentanyl
- Other pharmaceuticals: linezolid, triptans, valproate, lamotrigine, bromocriptine, methylene blue
- Recreational drugs: methamphetamine and other amphetamines, cocaine, serotonergic hallucinogens (MDMA, psilocybin, tryptamine derivatives)
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Bhat, Pavat, et al., editors. "Serotonin Syndrome." Washington Manual of Medical Therapeutics, 35th ed., Wolters Kluwer Health, 2016. The Washington Manual, www.unboundmedicine.com/washingtonmanual/view/Washington-Manual-of-Medical-Therapeutics/602695/all/Serotonin_Syndrome.
Serotonin Syndrome. In: Bhat PP, Dretler AA, Gdowski MM, et al, eds. Washington Manual of Medical Therapeutics. Wolters Kluwer Health; 2016. https://www.unboundmedicine.com/washingtonmanual/view/Washington-Manual-of-Medical-Therapeutics/602695/all/Serotonin_Syndrome. Accessed March 26, 2023.
Serotonin Syndrome. (2016). In Bhat, P., Dretler, A., Gdowski, M., Ramgopal, R., & Williams, D. (Eds.), Washington Manual of Medical Therapeutics (35th ed.). Wolters Kluwer Health. https://www.unboundmedicine.com/washingtonmanual/view/Washington-Manual-of-Medical-Therapeutics/602695/all/Serotonin_Syndrome
Serotonin Syndrome [Internet]. In: Bhat PP, Dretler AA, Gdowski MM, Ramgopal RR, Williams DD, editors. Washington Manual of Medical Therapeutics. Wolters Kluwer Health; 2016. [cited 2023 March 26]. Available from: https://www.unboundmedicine.com/washingtonmanual/view/Washington-Manual-of-Medical-Therapeutics/602695/all/Serotonin_Syndrome.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Serotonin Syndrome
ID - 602695
ED - Williams,Dominique,
ED - Bhat,Pavat,
ED - Dretler,Alexandra,
ED - Gdowski,Mark,
ED - Ramgopal,Rajeev,
BT - Washington Manual of Medical Therapeutics
UR - https://www.unboundmedicine.com/washingtonmanual/view/Washington-Manual-of-Medical-Therapeutics/602695/all/Serotonin_Syndrome
PB - Wolters Kluwer Health
ET - 35
DB - The Washington Manual
DP - Unbound Medicine
ER -